Analysis of the key themes driving private equity deal activity reveals that electronic medical record (emr) systems accounted for 2 pharmaceutical deals announced in Q2 2024, worth a total value of $100m. The $100m investment by BlueCross BlueShield Venture Partners, Deerfield Management Co, Endeavour Capital Group, JDLinx, KPCB Green Growth Fund and Sandbox Industries in Lumeris was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
Smarter leaders trust GlobalData
In value terms, electronic medical record (emr) systems-related deal activity remained flat in Q2 2024 compared with the previous quarter and as compared to Q2 2023. Related deal volume increased by 100% in Q2 2024 versus the previous quarter.
The top-ranked financial advisors supporting these private equity deals in H1 2024 were KeyCorp; LEK; Milbank with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.
